Microbial products influence immunity after allogeneic hematopoietic stem cell transplantation (allo-SCT). In this context, the role of cathepsin E (Ctse), an aspartate protease known to cleave bacterial peptides for antigen presentation in dendritic cells (DCs), has not been studied. During experimental acute graft-versus-host disease (GVHD), we found infiltration by Ctse-positive immune cells leading to higher Ctse RNA-and protein levels in target organs. In Ctse-deficient allo-SCT recipients, we found ameliorated GVHD, improved survival, and lower numbers of tissue-infiltrating DCs. Donor T cell proliferation was not different in Ctse-deficient vs. wild-type allo-SCT recipients in MHC-matched and MHC-mismatched models. Furthermore, Ctse-deficient DCs had an intact ability to induce allogeneic T cell proliferation, suggesting that its role in antigen presentation may not be the main mechanism how Ctse impacts GVHD. We found that Ctse deficiency significantly decreases DC motility in vivo, reduces adhesion to extracellular matrix (ECM), and diminishes invasion through ECM. We conclude that Ctse has a previously unrecognized role in regulating DC motility that possibly contributes to reduced DC counts and ameliorated inflammation in GVHD target organs of Ctse-deficient allo-SCT recipients. However, our data do not provide definite proof that the observed effect of Ctse −/− deficiency is exclusively mediated by DCs. A contribution of Ctse −/− -mediated functions in other recipient cell types, e.g., macrophages, cannot be excluded.
is to liberate peptide epitopes for antigen presentation (9, 10) . Ctse was shown to be involved in antigen presentation of bacterial peptides in DCs, and it may also be important for the presentation of allogeneic peptides on MHC class II molecules (11) (12) (13) . Recent studies demonstrated an increase in Ctse protein expression or enzymatic activity in patients suffering from Parkinson disease (14) or Helicobacter pylori infections (15) . Ctse overexpression has been associated with several types of cancer (16) (17) (18) (19) (20) (21) and has been used as a predictive biomarker in patients with malignant diseases (22) (23) (24) . The role of Ctse for the pathophysiology of GVHD has not been studied experimentally.
To be able to analyze the impact of Ctse in vivo, we have previously created Ctse-null mice, which have a normal phenotype (25) . OVA-antigen processing and presentation by DCs showed no difference in Ctse +/+ and Ctse −/− mice in vivo under non-inflammatory conditions. In experimental models of allergic airway inflammation, we found that Ctse deletion results in a reduced inflammatory response, marked by impaired lymphocyte infiltration into lungs in comparison to wild-type (WT) littermates (25) . In the current study, we examined the role of Ctse during GVHD after allo-SCT and its influence on DC function. 
MaTerials (Or sUBJecTs) anD MeThODs

Mice
conditioning regimen
Busulfan (Sigma-Aldrich, St. Louis, MO, USA) was dissolved in DMSO (40 mg/ml) and cyclophosphamide monohydrate (Sigma-Aldrich) in sterile water (10 mg/ml). Female C57BL/6 received IP doses of busulfan (20 mg/kg/day) for 4 days, followed by cyclophosphamide (100 mg/kg/day) for 2 days. Days -2 and -1 prior to HSCT were resting days.
Bone Marrow (BM) Transplantation (stem cell Transplantation, scT)
We have recently described a chemotherapy-based MHCmatched miHA-mismatched murine GVHD model, which may better resemble human GVHD as compared with traditional radiation-based MHC-mismatched models (26) . In this model, C57BL/6 mice are used as allo-SCT recipients. Therefore, we were able to use this specific model for all studies investigating Ctse −/− on the recipient side. For investigation of Ctse −/− on the donor side, we had to use an alternative model, because no reliable chemotherapy-based miHA-mismatched models exist with C57BL/6 mice on the donor side. We opted for the next best situation and used a haploidentical model for testing of Ctse −/− on the donor side. Recipient C57BL/6 mice were injected i.v. with 1.5 × 10 7 BM cells and 2 × 10 6 splenic T cells from LP/J (allogeneic) and C57BL/6 (syngeneic) donor mice on day 0. BM from the tibia and femur was flushed with isolation buffer (PBS/2% FCS/1 mM EDTA) and single-cell suspension was prepared by gently passing through a 23G needle and over a 70 μm cell strainer (BD Biosciences, San Jose, CA, USA). Splenocytes were passed through a 40 μm cell strainer. Erythrocytes were lysed with ammonium chloride buffer (Sigma-Aldrich). Splenic T cell was obtained using the mouse Pan T Cell Isolation Kit II (Miltenyi Biotec, Bergisch Gladbach, Germany) according to manufacturer's instructions. T cell purity was analyzed by CD3 staining and FACS analysis.
gVhD Monitoring
Mice were individually scored twice a week for five clinical parameters (posture, activity, fur, skin, and weight loss) on a scale from 0 to 2. Clinical GVHD score was assessed by summation of these parameters. Survival was monitored daily.
Tumor experiments C57BL/6 mice received 1 × 10 6 EL4 (C57BL/6) T cell lymphoma tumor cells stably expressing firefly luciferase intravenously. Tumor growth was measured by bioluminescence imaging. 3 mg/ mouse d-luciferin (Xenogen, Alameda, CA, USA) was injected i.p., mice were anesthetized and placed in an IVIS 200 system. Average radiance (p/s/cm 2 /sr) was determined using the Living Image 3.1 software (PerkinElmer, Waltham, MA, USA).
Facs analysis
Peripheral blood was lysed for 10 min with ammonium chloride. BM, spleen, lymph node, and thymus were prepared consistent to the BMT Protocol. Single-cell suspensions were washed two times, collected in MACS buffer (PBS/0.5 mM EDTA/0.5% BSA), and stained for 20 min at 4°C with rat anti-mouse antibodies from BD Biosciences. Antibodies used are anti-Ly9.1-PE (30C7), APC-conjugated anti-CD8a (53-6.7), PerCP-Cy5.5-conjugated anti-CD45R/B220 (RA3-6B2), FITC-conjugated anti-H2kb (AF6-88.5), PE-Cy7-conjugated anti-CD4 (RM4-5), anti-CD11c (HL3), APC-Cy7-conjugated anti-CD3e (145-2C11), and PerCPCy5.5-conjugated anti-mouse CD86 (GL-1). Samples were analyzed using a BD FACSCanto II (BD Biosciences) and FlowJo 7.6.5 Software (Tree Star Inc., Ashland, OR, USA).
histology
Tissue samples were harvested and cryo-embedded in TissueTek optimum cutting temperature compound (Sakura Finetek, Alphen aan den Rijn, Netherlands). Cryosections (5 μm) were acetone fixed at −20°C. Histopathological score was assessed on H&E-stained sections after Lerner criteria (27) and grade of liver inflammation [slight (1) or marked (2) portal/venous and marked lobular (3) inflammation]. Sections for analysis of lymphocyte infiltration were blocked by PBS/3% BSA/5% FCS and stained over night at 4°C with primary rat anti-mouse antibodies against, CD11c (HL3), CD4 (H129. 19) , and CD8a (53-6.7) from BD Biosciences. Binding was visualized with secondary donkey anti-rat antibody conjugated with Alexa Fluor 488 or Cy3 (Life Technologies) and nuclear counterstain was performed using 4,6-diamidino-2-phenylindole (Sigma-Aldrich). Five sections per sample were investigated with a Motic BA410 epifluorescence microscope (Motic, Hong Kong) and quantification was assessed by calculating CD11c
+ , or CD8 + area against total liver parenchyma or colon mucosal area with a predetermined threshold using Fiji Software (http://fiji.sc/Fiji).
image acquisition
Fluorescence and bright-field images were taken using a Motic BA410 microscope with a Moticam Pro 285B and the Motic Images Plus 2.0 software. The used objectives were Plan Fluar 10×/0.30, 20×/0.50, and 40×/0.75. Adobe Photoshop CS6 was used for image processing.
anti-Mouse ctse Polyclonal antibody generation
The following peptide sequence of mouse Ctse: SLITGPPDKIKQLQE, which represents amino acids 286-300 of the mouse Ctse protein was chosen for immunization. Immunization of rabbits was done with the specific mouse Ctse peptide bound to a protein carrier (KLH) for 6 months, boosting once per month. Rabbit serum was isolated from positively tested animals, and the IgG fraction was purified.
Dc generation
Dendritic cells (Ctse +/+ and Ctse −/− ) were generated from fresh isolated BM cells grew in CellGro DC medium (CellGenix) containing 10% FCS (Pan Biotech), IL-4 (10 ng/ml) (R&D), and GM-CSF (10 ng/ml) (GIBCO). Medium was changed on days 2 and 4. On the seventh day, cells were analyzed by flow cytometry using the markers CD11c, F4/80, CD14, MHCII, CD11b, CD80, CD86, CD45, CD3, and CD19. ) were anesthetized with Ketamin/Rompun (1:1). FITC (SIGMA) (10 mg/ml) was dissolved in equal volumes of acetone/dibutylphthalate (1:1) and applied with a pipet tip to the ear skin and the dorsal skin of Ctse +/+ and Ctse −/− mice. Lymph nodes (inguinal, mandibulares, retropharyngeus lateralis, axillaris, accesorius, and brachial) were removed 24 h later. Cell suspensions of total lymph nodes were prepared by straining the nodes through a nylon mesh filter (70 μm) and analyzed by flow cytometry. CD11c was used as DC marker. A total of 50,000 cells were counted and the relative migration of DCs was calculated by dividing the CD11c + DCs through the sum of FITC + CD11c + DCs and CD11c + DCs.
adhesion assay
The adhesion of DCs (Ctse +/+ and Ctse −/− ) was measured with the xCELLigence system (Roche) using E-plates (16 wells). Cells adhere to the bottom of the wells and lead to a change in the electrical impedance, which is measured by gold microelectrodes.
The more cells adhere the higher increases the electrical impedance, which is displayed as Cell Index. The E-plates were coated with different substrates: collagen I 1.73 mg/ml (BD Biosciences), fibronectin 10 μg/ml (Sigma), and matrigel 9 mg/ml (Cultrex). A total of 50,000 DCs were activated with LPS in the well (4 μg/ml). Cell adhesion was measured within 2 h.
invasion assay
Invasion of Ctse
+/+ and Ctse −/− DCs was investigated with xCELLigence system (Roche). Microporous membrane (3 μm) in CIM-plates was either coated with a 1-mm thick layer of collagen I 1.73 mg/ml (BD Biosciences) or matrigel 9 mg/ml (Cultrex). The gold microelectrodes are attached below the membranes. A total of 80,000 DCs (Ctse +/+ and Ctse −/− ) were seeded on coated membranes in the upper compartment in the presence of LPS (4 μg/ml). In the lower compartment, medium with chemokines CCL21 (500 ng/ml) and CCL19 (500 ng/ml), both acting as CCR7 ligands, was present as a chemoattractant.
In Vivo T cell Proliferation assay C57BL/6 Ctse −/− or C57BL/6 WT littermates were conditioned with chemotherapy as described above. CD3
+ lymphocytes were isolated from spleens of either Balb/C or 129/J mice using mouse Pan T cell isolation Kit II (Miltenyi Biotec, Bergisch Gladbach, Germany) according to manufacturer's instructions. Cells were loaded with CFSE (carboxyfluorescein diacetate, succinimidyl ester) at a final concentration of 2.5 μmol for 8 min at 37°C in 10% FCS/PBS. 5 × 10 6 CFSE-loaded CD3 + cells were injected i.v. into the tail vein at day 0. Ninety-six hours later, mice were sacrificed, spleens and lymph nodes were taken and cells were isolated. After staining with the appropriate donor marker (H2kd for Balb/C and Ly9 for 129/J), cell samples were analyzed using a BD FACSCanto II (BD Biosciences) and FlowJo 7.6.5 Software (Tree Star Inc., Ashland, OR, USA).
Mixed leukocyte reaction (Mlr)
Dendritic cells were isolated from spleen of C57BL/6 Ctse −/− and WT mice using a CD11c
+ isolation kit and splenic T cells from LP/J mice were obtained using the mouse Pan T cell isolation Kit II (Miltenyi Biotec, Bergisch Gladbach, Germany) according to the manufacturer's instructions. DCs were treated with 100 ng/ ml LPS or left untreated for 4 h. T-cells were loaded with CFSE (5-(and-6)-carboxyfluorescein diacetate, succinimidyl ester, Thermo Fisher). 2.5 × 10 4 DCs (activators) and 2.5 × 10 5 T-cell (responders) were put together for 96 h in an incubator at 37°C and 5% CO2. FACS analysis was done measuring total cell counts positive for CFSE and CD3. Proliferating cells are determined as cells, showing less CFSE load compared to control samples with only CFSE-loaded T-cells.
real-time Pcr
RNA and cDNA were obtained using the RNeasy Mini Kit (QIAGEN, Venlo, Netherlands) and the QuantiTect Reverse Transcription Kit (QIAGEN) after manufacturer's instructions. Real-time PCR amplification reaction (50°C for 2 min, 95°C for 10 min, 49 cycles of 95°C for 10 s, 60°C for 1 min) was performed on DNA Engine Opticon (BioRad, Hercules, CA, USA) using the TaqMan Gene Expression Master Mix (Life Technologies) and primers and probes (BioTez GmbH, Berlin, Germany) designed with the Primer Express 1.5 software (Life Technologies). Data were analyzed with the Opticon Monitor 3.1 analysis software (BioRad) and the comparative CT method (ΔΔCT method).
statistics Survival data were analyzed using the Kaplan-Meier method and compared with the Mantel-Cox log-rank test. For statistical analysis of all other data, rank sum tests were used, unless indicated otherwise. Values are presented as mean ± SEM. Values of p ≤ 0.05 were considered statistically significant. All statistical analyses were performed using GraphPad Prism software (GraphPad Software Inc., La Jolla, CA, USA).
resUlTs ctse is Overexpressed in Target Organs during acute gVhD
First, we analyzed the expression profile of Ctse in target organs during acute GVHD in the murine MHC-matched, miHAmismatched LP/J→C57BL/6 (B6) allo-SCT model (26) . Using qPCR and the comparative ΔΔCT method, we found a significant increase in Ctse mRNA levels in allo-SCT recipients with GVHD (aGVHD) relative to syngeneic (no GVHD) SCT recipients without GVHD in colon (mean: 5.58-fold increase in aGVHD vs. no GVHD, p = 0.003) and liver (mean: 3.87-fold increase in aGVHD vs. no GVHD, p = 0.045) at day +15 after allo-SCT (Figures 1A,B) . Of note, the mean absolute mRNA expression level of Ctse in colon was more than 10 times higher as compared with liver (data not shown). In our hands, no commercially available antibody against Ctse worked in histology. Therefore, we produced a polyclonal rabbit anti-murine Ctse antibody choosing a different mouse Ctse peptide epitope for immunization as described in the Section "Materials (or subjects) and Methods. " We checked the antibody for its specificity using Ctse KO and WT tissues in immunofluorescence, obtaining no staining in Ctse KO tissues. Using this antibody in immunofluorescence analysis of cryosections, we confirmed that mRNA expression correlated with protein levels. In liver, protein expression was nearly undetectable, reflecting the results of the low mRNA expression level. Ctse protein expression was specifically increased in CD11c ). After chemotherapy with busulfan and cyclophosphamide, recipients received T cell-depleted BM (TCD-BM) and GVHD was induced by the addition of donor splenic T cells to the allograft. We used Ctse −/− donors and WT littermate donors as the source for TCD-BM or T cells. We did not detect significant differences in lethal GVHD between the two different groups (Figure 2A) . Furthermore, we did not detect differences in clinical GVHD scores in allo-SCT ) model to investigate Ctse deficiency in allo-SCT recipients (26) . We found significantly less lethal GVHD in B6 Ctse −/− allo-SCT recipients as compared to B6 WT littermate allo-SCT recipients ( Figure 2C) . We performed investigator-blinded scoring for clinical GVHD symptoms and found significantly reduced clinical GVHD scores in Ctse −/− allo-SCT recipients vs. WT littermate allo-SCT recipients ( Figure 2D) . To analyze target organ GVHD, we performed histopathological analyses and found less GVHD in the liver and a trend toward less GVHD in colon (Figures 3A,B,D,E) . The numbers of tissue-infiltrating alloreactive T-lymphocytes were reduced in Ctse −/− allo-SCT recipients in GVHD target organs colon and liver (Figures 3C,F) at peak GVHD development on day +16 following BMT, demonstrating less GVHD-related target organ inflammation.
analyses of systemic inflammation during gVhD in ctse-Deficient vs. WT allo-scT recipients
To analyze the impact of Ctse deficiency on engraftment and on systemic inflammation during GVHD, we sacrificed Ctse −/− allo-SCT recipients and WT allo-SCT recipients in the LP/J (H2 b )→C57BL/6 (H2 b ) model at day +16 after allo-SCT. We harvested blood, BM, thymus, spleen, and peripheral lymph nodes for flow cytometric analyses. In these experiments, we found similar numbers for donor chimerism and for most lymphoid and myeloid cell populations in the blood, BM, thymus, spleen, and peripheral lymph nodes of Ctse-deficient vs. WT allo-SCT recipients ( Figures S1-3 in Supplementary Material). Of note, we found no significant differences of donor T cell numbers in blood and spleen ( Figures S2 and S3 in Supplementary Material). However, in lymph nodes, we found significantly reduced CD8
+ T cell counts in Ctse-deficient allo-SCT recipients vs. WT allo-SCT recipients (Figures 4A,B) . The number of donor CD8 + T cells were reduced (Figure 4B ), leading to an overall reduction of total CD8 + T cells ( Figure 4A ). Due to these results and because of the previously described role of Ctse on antigen presentation, we wanted to determine the impact of Ctse deficiency on proliferation of allogeneic donor T cells. Ctse KO C57BL/6 mice and WT littermates were conditioned with chemotherapy and CFSE-labeled, miHA-mismatched CD3 + lymphocytes from 129J donors or CD3 + lymphocytes from Balb/c (major MHC mismatch) were injected i.v. into the tail vein. Ninety-six hours later, cells were isolated from spleen and lymph nodes for flow cytometric analyses. Figure S4 in Supplementary Material). Taken together, we found in our model and assays no major impact of Ctse on the ability of DCs to induce alloactivation of donor T cells.
To further investigate the impact of Ctse deficiency of the allo-SCT recipient on host DCs, we analyzed DC numbers and activation status during GVHD in BM, lymph nodes, and spleen. We found no significant differences in DC counts between Ctse-deficient allo-SCT recipients vs. WT allo-SCT recipients in lymph nodes. However, there was a non-significant trend toward reduced CD11c
+ DC numbers in BM and spleen ( Figures 4E,F) as well as a trend toward lower MHCII expression on live cells and CD86 expression of Ctse-deficient DCs during GVHD (Figures 4G,H) . Other activation markers, like CD40 and CD80, were found to be expressed similar in Ctse-deficient vs. WT animals at day +16 post BMT (data not shown). Of note, at the day of analysis (day +16 post allo-SCT) around 60-70% of all cells in the investigated lymphoid organs were donor marker Ly9.1 negative.
The numbers of Tissue-infiltrating Dcs is reduced in livers of ctse-Deficient alloscT recipients during gVhD Next, we were interested in tissue-infiltrating DCs during GVHD. For analyses, we chose liver and omitted colon because in colon CD11c expression is found on a substantial proportion of macrophages, which is a confounder (28) . We used the LP/J (H2 b )→C57BL/6 (H2 b ) model and found significantly less liverinfiltrating CD11c
+ cells in Ctse-deficient allo-SCT recipients vs. WT allo-SCT recipients (Figures 5A,B) . In addition, we found reduced numbers of tissue-infiltrating CD8 + T cells in liver and colon of Ctse-deficient allo-SCT recipients during GVHD (Figures 5C,D) . Again, CD4
+ T cell infiltration into liver and colon was found to be only slightly reduced and was not statistically significant (Figures 5E,F) .
The Motility of ctse-Deficient Dcs is impaired
In our experiments, the reduced DC counts in liver in Ctse −/− allo-SCT recipients during GVHD were striking. Importantly, overexpression of Ctse has been shown by different groups to increase the invasive and migratory capacity of cancer cells (24, 29, 30) , raising the possibility that Ctse is a positive regulator of cell motility. Additionally, it was shown by Chen et al. (31) and Reichardt et al. (32) that DC motility influences GVHD development. We therefore hypothesized that Ctse deficiency does have an influence on DC motility, thus leading to reduced migration of DCs to target organs and a lower degree of ti ssue , and (h) Matrigel™ (9 mg/ ml; n = 3). Error bars indicate mean ± SD, p-values were calculated using non-parametric Kruskal-Wallis ANOVA and a post hoc Mann-Whitney U-test (B), the two-sided two sample t-test (c) or two-sided one-sample t-test for the normalized data in panels (e,g,h). inflammation in Ctse-deficient allo-SCT recipients during GVHD. Following our hypothesis, we analyzed DCs from Ctse −/− and WT animals for important motility characteristics of APCs. In an FITC ear paint assay (Figure 6A ), we found a 60% reduction in FITC + CD11c + cell counts in the draining lymph nodes of Ctse −/− mice as compared to WT mice ( Figure 6B) . Interestingly, we ( Figure 6C ) and others could not show any significant difference in transwell migration of Ctse-deficient DCs compared to WT DCs following a chemoattractant stimulus (11) . The movement of cells in vivo is, however, not solely dependent on their intrinsic motility but also depends on the ability to form contacts with the extracellular matrix (ECM) and to actively transmigrate through matrix-rich areas. While adhesion to ECM components is one important step in entering, for example, vascular structures, to migrate from the periphery to distant locations, like lymph nodes and other tissues in vivo, the second crucial step is transmigration through these ECM structures like the basal membrane of endo-and epithelial layers. Here, we could show that both steps in this process, the adhesion to (Figures 6D,E and the transmigration through ECM substrates like collagen and matrigel (Figures 6F-H) , were markedly reduced between 40 and 80% in in vitro assays using Ctse-deficient DCs compared to WT DCs. We conclude that Ctse is involved in regulating the motility of DCs.
analysis of the impact of ctse Deficiency on Tumor growth
A possible role of Ctse in antitumor immunity has been suggested by others (33, 34) . We therefore studied the role of Ctse in antitumor responses in C57BL/6 WT mice vs. C57BL/6 Ctse −/− mice ( Figure 7A ). Mice were challenged intravenously with EL4 T cell lymphoma cells. We found no significant differences in tumorassociated mortality and survival ( Figure 7B) . In bioluminescence imaging, we found no significant differences of tumor growth in Ctse −/− mice vs. WT mice at most time points ( Figure 7C) . However, at the earliest time point that we chose for imaging (day 14 after tumor challenge), tumor load was moderately, but significantly, higher in Ctse −/− mice vs. WT mice ( Figure 7D ). Taken together, our data argue against a major impact of Ctse on immunity against EL4 lymphoma.
DiscUssiOn
We found upregulation of Ctse in target organs during GVHD that was mainly caused by tissue infiltration of Ctse-expressing immune cells, such as CD11c + cells. Our data, positively, connect to previous reports on increased Ctse activity in inflammatory and infectious diseases (14, 15) . The restriction of Ctse expression to immune cells is in line with previous publications showing that Ctse is predominantly expressed in antigen-presenting cells (6, 8) . Furthermore, it was shown that Ctse was not expressed in T cells and we found its deficiency on the donor side had no significant influence on GVHD, suggesting that Ctse has no important direct impact on alloactivation of T cells.
Using Ctse −/− and WT littermate transgenic mice, we found that Ctse deficiency in allo-SCT recipients ameliorates acute GVHD. In histology, the effect of Ctse deficiency on target organ histology was stronger in liver, as compared with colon ( Figure 3) . In contrast, when we used Ctse −/− and WT littermate transgenic mice as allo-SCT donors, we found no significant impact on GVHD. These results demonstrate that the Ctse deficiency on the recipient side is involved in GVHD regulation. Our data provide novel evidence on the significant biologic role of Ctse in alloreactivity and inflammation. This information adds to the existing evidence on the important role of molecules that are involved in sensing and processing of bacterial peptides, such as nod-like-receptors and toll like receptors (2). To our knowledge, this is the first report on the role of Ctse during allo-SCT. One previous report associated Cathepsin S (Ctss), a lysosomal cysteine protease, with the development of GVHD. Ctss mRNA expression and activity was upregulated after allo-SCT. However, the pharmacologic inhibition of Ctss led to increased GVHD, possibly because of cross presentation to MHC class I (35) . Our data on Ctse during GVHD are in line with our previous publication on reduced inflammation in asthma models in Ctse −/− mice (25) . However, our findings are in some (11) . These discrepancies might be due to variable cell type-and antigen-specific roles of proteases in antigen presentation, and also highlights the importance of systematic and careful dissection of the role of Ctse for DC function in complex in vivo systems such as our GVHD model.
To investigate the mechanism how Ctse influences GVHD, we were first interested in the ability of antigen-presenting cells, such as DCs, to induce allogeneic T cell proliferation. In MHC-matched and MHC-mismatched models, we found that Ctse deficiency in antigen-presenting cells had no major impact on alloactivation of WT donor T cells in vivo and in vitro. Although robust data exist showing that Ctse has important functions in antigen presentation, our data argue against a major biologic relevance of Ctse-mediated antigen presentation during GVHD. In search for alternative mechanisms how Ctse regulates GVHD, we became interested in DC motility because of the significantly reduced DC numbers we found during hepatic GVHD in Ctse-deficient allo-SCT recipients. We demonstrated that Ctse deficiency results in profoundly impaired DC motility and adhesion to and migration through ECM. These results might be the explanation for the reduced DC numbers in GVHD target organs of Ctse-deficient mice compared to WT animals. To our knowledge, this is the first report on the impact of cathepsin proteases during DC motility. Of note, we found no significant differences in DC numbers in lymph nodes of Ctse-deficient allo-SCT recipients vs. WT allo-SCT recipients. Based on previous knowledge and our experimental data, we are currently unable to provide a mechanistic explanation of this discrepancy between DC numbers lymph nodes and the liver. Another limitation of our study is, that we were unable to prove, that the observed effects are mediated by Ctse activity in DCs. It is also possible that Ctse-mediated effects in other recipient cell types, e.g., in macrophages, may have contributed to the observed effects. Others (31, 32) have shown that either miR-155 deficiency in the recipient DC compartment or rapamycintreated host DCs led to impaired GVHD development. In both studies, the motility of DCs was shown to be affected as well as the expression of surface receptors and cytokine expression in the investigated DC populations. In addition, it has previously been demonstrated that Ctse expression in cancer cells is associated with increased invasiveness, linking Ctse to cell motility (24, 29, 30) . Others could show decreased DC motility in mice deficient for syndecan-4 or heparanase (36, 37) . Similar to Ctse, both proteins are related to ECM interaction and degradation, and in both cases, reduced DC motility led to reduced inflammation in the respective models. Regarding clinical development, Ctse is a feasible target for small molecule inhibitors, like pepstatin A (38) or other aspartic protease inhibitors (39) . Taken together, previous studies provided evidence for the biologic significance of DC motility. Our findings on reduced DC motility in Ctse-deficient mice provide a possible link between microbial products and DC motility. 
